The first DRIVE-AB stakeholder meeting, organized by the DRIVE-AB communications team in conjunction with Chatham House, took place on Monday, 9 February 2015, 10.00-17.00 at The Royal Automobile Club in London.
CEOs and their representatives from 30 small- and medium-sized European companies (SMEs) with antibacterial R&D programmes were invited along with participants from WP2. The object was for them to learn about what DRIVE-AB was hoping to achieve and for DRIVE-AB participants to seek to understand the challenges faced by SMEs in the discovery and development of potential new products.
Participants were divided into four round-tables to discuss a series of questions devised by Work Package 2, the team responsible for developing new economic models, and there were lively and informative discussions. Evaluation suggests a very positive response with 95% of participants giving an ‘excellent’ or ‘good’ assessment of the round-table. In the final session participants discussed the modalities of forming a European antibacterial SME group to represent their interests to the European Commission, which will now be taken forward.
DRIVE-AB Communications co-leader Ursula Theuretzbacher kicked off the meeting with a presentation about “DRIVE-AB and the role of SMEs in antibacterial drug R&D“.
Please click to view the DRIVE-AB Stakeholder Meeting Report.